CURRENT PRACTICE STUDY OF ANTIBIOTIC TREATMENT OF GASTRIC MALT LYMPHOMA
OBJECTIVES: I. Evaluate the response of gastric lymphoma of mucosa-associated lymphoid
tissue (MALT) to treatment for Helicobacter pylori infection with antibiotics (amoxicillin,
clarithromycin, tetracycline, and metronidazole) and with gastric acid inhibitors
(omeprazole and bismuth subsalicylate). II. Correlate response with endoscopic tumor grade
and clinical and pathological parameters. III. Assess the incidence of H. pylori infection
in patients with gastric MALT lymphoma.
OUTLINE: All patients are treated on Regimen A; those receiving tetracycline on Regimen A
are switched to Regimen B for their second course; those receiving amoxicillin for their
first course receive tetracycline for their second course. Regimen A: Antibiotic Therapy
with Gastric Acid Inhibition. Amoxicillin (or Tetracycline in penicillin-allergic patients);
Clarithromycin; with Bismuth Subsalicylate; Omeprazole. Regimen B: Antibiotic Therapy with
Gastric Acid Inhibition. Tetracycline; Metronidazole, METRO, NSC-50364; with Bismuth
Subsalicylate; Omeprazole.
PROJECTED ACCRUAL: 75 patients will be entered over 3 years.
Interventional
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Number of Patients with Response to Antibiotic Treatment of Gastric Malt Lymphoma
3 Years
No
Gideon Steinbach, MD, PhD
Study Chair
M.D. Anderson Cancer Center
United States: Federal Government
CPPDM95-084
NCT00002682
August 1995
October 2001
Name | Location |
---|---|
University of Texas - MD Anderson Cancer Center | Houston, Texas 77030-4009 |
MD Anderson Cancer Center Orlando | Orlando, Florida 32806 |